The webcast is expected to commence at approximately 9 a.m. ET on Thursday, December 14, 2017.
NORCROSS, Ga., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will present a corporate update via live webcast immediately following the business portion of its 2017 Annual Meeting of Shareholders. Peter Traber, M.D., president, chief executive officer and chief medical officer, will put the recent positive NASH-CX trial results in perspective for treating patients with NASH cirrhosis who currently have no therapies available. The webcast is expected to commence at approximately 9 a.m. ET on Thursday, December 14, 2017.
The webcast can be accessed via the investor relations portion of the Galectin Therapeutics website at http://investor.galectintherapeutics.com/. The presentation can be heard via teleconference by dialing 866-225-1342 (within the United States). A list of international dial-in numbers can be found here. The passcode for participants is 2856445641.
Please log in approximately 10 minutes before the event to ensure a timely connection. You may also test your connection prior to the start of the presentation by visiting:
https://dentons.adobeconnect.com/common/help/en/support/meeting_test.htm
The webcast will be archived on the Company’s website.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Contact
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
